Pacira Pharmaceuticals (NSDQ:PCRX) said today that it has signed a deal to acquire Myoscience and its pain relief device for up to $220 million. Myoscience’s iovera system is designed to safely freeze nerves while protecting surrounding tissue. As part of the deal that is slated to close by early April, Pacira plans to incorporate the iovera […]
Pacira Pharmaceuticals
Pacira shares fall after FDA committee rejects expanded use for Exparel pain drug
Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell nearly -16% today after a panel of experts convened by the FDA voted against an expanded use for Pacira’s injectable pain drug. The pharmaceutical company previously submitted an application seeking to use the local anesthetic as a regional pain-killer. The committee’s feedback doesn’t necessarily mean the immediate end for Pacira’s […]
Pacira to invest up to $25m in surgical reconstruction company
Pacira Pharmaceuticals (NSDQ:PCRX) plans to invest up to $25 million in privately-held surgical reconstruction company Tela Bio, the company said today. Pennsylvania-based Tela Bio has a portfolio of reinforced bioscaffold products, called OviTex, which combine biologic and synthetic materials in an embroidered implant that allows fluid and cells to move freely through the device. The implants […]
Pacira misses on Q2 sales, earnings
Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell slightly today after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The Parsippany, N.J.-based company posted a net loss of -$19.7 million, or -49¢ per share, on sales of $70.9 million for the 3 months ended June 30, for bottom-line loss of -148% on sales […]
Pacira halts DepoCyt production over manufacturing issue
Pacira Pharmaceuticals (NSDQ:PCRX) said late last month that it plans to stop producing its liposomal chemotherapeutic due to “persistent technical issues specific to the DepoCyt(e) manufacturing process.” In a regulatory note filed to the SEC, the N.J.-based company said it expects a charge of $5 million thanks to the discontinuation, including $500,000 related to employee lay-offs. […]
Insulet brings on new chief commercial exec | Personnel Moves – June 5, 2017
Insulet (NSDQ:PODD) last month named Bret Christensen as its chief commercial officer to lead the company’s sales, marketing, customer care, market access and advocacy. He most recently served as GM of Myriad Genetics’ preventive care business division. He has also worked as VP of sales and marketing of the gynecologic surgical products unit at Hologic. “I […]
Pacira touts Phase IV study of Exparel anesthetic in total knee arthroplasty
Pacira Pharmaceuticals (NSDQ:PCRX) said today the Phase IV study of its Exparel bupivacaine liposome injection in patients undergoing total knee arthroplasty met its co-primary endpoints for postsurgical pain and opioid reduction. The anesthetic achieved statistical significance for secondary endpoints including time to 1st opioid use and the percentage of patients who did not require opioids […]
Pacira prices $300m senior notes offering
Pacira Pharmaceuticals (NSDQ:PCRX) said today that it priced $300 million of convertible 2.375% senior notes due 2022 in a private placement to qualified institutional buyers. The Parsippany, N.J.-based company also gave purchasers a 30-day option to buy an additional $45 million aggregate principal amount of notes. The company expects to bring in about $290 million […]
InSitu Biologics touts preclinical data for non-opiate hydrogel painkiller
InSitu Biologics touted preclinical data for its non-opiate, hydrogel-based painkiller, AnestaGel, for use in peri-operative regional pain management. The St. Paul, Minn.-based company designs therapies using its Matrix biohydrogel material. Independent tests compared operative site injections of AnestaGel and Pacira Pharmaceutical’s (NSDQ:PCRX) Exparel. According to InSitu, the data showed that AnestaGel lasted longer and provided a […]
Touch Surgery, Pacira to develop knee surgery sim
Touch Surgery and Pacira Pharmaceuticals (NSDQ:PCRX) launched the Exparel knee training simulation for the Touch Surgery app, designed to provide clinicians with a virtual training experience for administering the bupivacaine liposome injectable suspension in total knee arthroplasty. The simulation includes a 3D environment where clinical decisions and viewpoints are all dictated by the user and simulates […]
